BRIEF-Fulcrum Therapeutics Approves Restructuring Plan After Discontinuing Pociredir For Sickle Cell Disease

Fulcrum Therapeutics

Fulcrum Therapeutics

FULC

0.00

June 4 (Reuters) - Fulcrum Therapeutics Inc FULC.O:

  • FULCRUM THERAPEUTICS - APPROVES RESTRUCTURING PLAN AFTER DISCONTINUING POCIREDIR FOR SICKLE CELL DISEASE - SEC FILING

  • FULCRUM THERAPEUTICS - TO REDUCE WORKFORCE BY 85% FROM 57 TO 9 EMPLOYEES, COMPLETION EXPECTED Q2 2026 - SEC FILING

  • FULCRUM THERAPEUTICS - EXPECTS AGGREGATE RESTRUCTURING CHARGES OF ABOUT $4.2 MILLION - SEC FILING

  • FULCRUM THERAPEUTICS - WORKFORCE REDUCTION COMMUNICATED JUNE 4, 2026; CHARGES TO BE INCURRED IN Q2 2026 - SEC FILING

Further company coverage: FULC.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.